Highlight
Anti-PD-1 therapy exploits near-universal PD-L1/PD-L2 overexpression in classical Hodgkin lymphoma, resulting from 9p24.1 alterations on Reed-Sternberg cells, leading to remarkable and durable treatment responses.
Nivolumab-based regimens, such as Nivo-AVD, are now emerging standards in both advanced and early unfavorable stages of classical Hodgkin lymphoma, with excellent safety profiles and improved survival outcomes.
Specialty calculators
For clinical reference; use professional judgment.
